| 19038 |
Alutard SQ® honey bee and Alutard SQ® wasp venoms |
Alutard SQ® |
As allergy immunotherapies for patients with a documented history of generalised and/or systemic IgE-mediated allergic reactions due to sensitisation to honey bee venom (Apis mellifera) and wasp venom (Vespula spp.), respectively. |
Rapid Review Complete |
11th March 2020 |
 |
| - |
Burosumab |
Crysvita® |
Treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. |
NCPE Assessment Process Complete |
12th March 2020 |
|
| 20012 |
Infliximab |
Remsima SC® |
In combination with methotrexate, is indicated in rheumatoid arthritis for the reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs. |
Rapid Review Complete |
24th March 2020 |
|
| - |
Olaparib |
Lynparza® |
For the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. |
Assessment process complete |
30th March 2020 |
|
| 20003 |
Pegaspargase |
Oncaspar® |
As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia in paediatric patients from birth to 18 years. |
Rapid Review Complete |
13th March 2020 |
|
